PI
COGT icon

PEAK6 Investments’s Cogent Biosciences COGT Stock Holding History

PEAK6 Investments’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$134K – 3672
2024
Q1 		$134K Buy
+20,000
New +$124K ﹤0.01% 3248

Other funds holding COGT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PEAK6 Investments's COGT Position: Q4 2023 in Review

PEAK6 Investments sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 23,224 shares — an estimated $226K sold.

PEAK6 Investments first reported a position in COGT in Q2 2022 and held it in 3 quarters. The position peaked at $226K in Q3 2023. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

  • PEAK6 Investments reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
  • PEAK6 Investments sold 23,224 Cogent Biosciences shares in Q4 2023, an estimated $226K.
  • PEAK6 Investments first reported a position in Cogent Biosciences in Q2 2022 and held it in 3 quarters.
  • PEAK6 Investments's Cogent Biosciences position peaked at $226K in Q3 2023.
  • 144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.